F2G Tops Up Funds For Launch Of New Class Of Antifungal
UK Firm To Go It Alone With US Commercialization
Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.
You may also be interested in...
Faced with a scarily short cash runway and an ongoing expensive mid-stage study of an allogeneic cell therapy for the treatment of delayed-union bone fractures, Bone Therapeutics has found a saviour in France's Medsenic.
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.